Telefonica Brasil S.A Stock Hits New 52-Week Low (VIV)
Telefonica Brasil S.A (NYSE:VIV) hit a new 52-week low Tuesday as it is currently trading at $21.98, below its previous 52-week low of $22.02 with 603,890 shares traded as of 1 p.m. ET. Average volume has been 1.8 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model NEW YORK ( TheStreet) -- Telefonica Brasil S.A (NYSE: VIV) hit a new 52-week low Tuesday as it is currently trading at $21.98, below its previous 52-week low of $22.02 with 603,890 shares traded as of 1 p.m. ET. Average volume has been 1.8 million shares over the past 30 days. Telefonica Brasil S.A has a market cap of $25.25 billion and is part of the technology sector and telecommunications industry. Shares are down 18% year to date as of the close of trading on Monday. Telefonica Brasil, S.A. provides fixed-line telecommunications services to residential and commercial customers in the state of Sao Paulo, Brazil. The company has a P/E ratio of 6.5, below the average telecommunications industry P/E ratio of 8.5 and below the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Telefonica Brasil S.A as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and a generally disappointing performance in the stock itself. You can view the full Telefonica Brasil S.A Ratings Report. See all 52-week low stocks or get investment ideas from our investment research center.